ATHROMBIN-K
Pre-Launchwarfarin potassium
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
ATHROMBIN-K (warfarin potassium) is 12.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATHROMBIN-K (warfarin potassium) is an oral anticoagulant that inhibits vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking VKORC1 enzyme activity. It is indicated for patients requiring systemic anticoagulation to prevent thromboembolism. Peak anticoagulant effect occurs 72-96 hours after administration, with an effective half-life of 20-60 hours.
Pre-Launch
Pre-launch stage indicates early-stage commercial planning; team expansion anticipated post-approval, but market entry strategy unclear given warfarin commodity market dynamics.
Mechanism of Action
12.1 Mechanism of Action Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.